George Fennell Sells 9,986 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stock

IDEXX Laboratories, Inc. (NASDAQ:IDXX) EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the transaction, the executive vice president now owns 8,176 shares of the company’s stock, valued at $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

IDEXX Laboratories Stock Down 0.3 %

IDEXX Laboratories stock opened at $463.74 on Wednesday. IDEXX Laboratories, Inc. has a fifty-two week low of $398.50 and a fifty-two week high of $583.39. The stock has a market cap of $37.98 billion, a PE ratio of 43.46, a price-to-earnings-growth ratio of 3.47 and a beta of 1.37. The firm’s 50-day simple moving average is $429.03 and its 200 day simple moving average is $453.28. The company has a debt-to-equity ratio of 0.28, a quick ratio of 1.03 and a current ratio of 1.31.

Analyst Upgrades and Downgrades

IDXX has been the subject of a number of analyst reports. Leerink Partnrs upgraded shares of IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. Morgan Stanley reduced their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. Bank of America lifted their price objective on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a report on Tuesday, February 4th. Piper Sandler lifted their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a report on Monday. Finally, Barclays boosted their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a report on Tuesday, February 4th. Four investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $533.75.

Institutional Trading of IDEXX Laboratories

Several hedge funds have recently added to or reduced their stakes in the stock. Segall Bryant & Hamill LLC bought a new stake in IDEXX Laboratories in the fourth quarter worth about $8,600,000. KLP Kapitalforvaltning AS bought a new stake in IDEXX Laboratories in the fourth quarter worth about $15,876,000. American Century Companies Inc. raised its position in IDEXX Laboratories by 30.9% in the fourth quarter. American Century Companies Inc. now owns 809,814 shares of the company’s stock worth $334,810,000 after acquiring an additional 191,385 shares during the period. Mizuho Securities USA LLC raised its position in IDEXX Laboratories by 45.4% in the fourth quarter. Mizuho Securities USA LLC now owns 7,761 shares of the company’s stock worth $3,209,000 after acquiring an additional 2,424 shares during the period. Finally, Quantbot Technologies LP raised its position in IDEXX Laboratories by 1,870.5% in the fourth quarter. Quantbot Technologies LP now owns 13,301 shares of the company’s stock worth $5,499,000 after acquiring an additional 12,626 shares during the period. Institutional investors own 87.84% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.